- Home
- DHT vs ANIP Comparison
DHT vs ANIP Comparison
Compare DHT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHT
- ANIP
- Stock Information
- Founded
- DHT 2005
- ANIP 2001
- Country
- DHT Bermuda
- ANIP United States
- Employees
- DHT N/A
- ANIP N/A
- Industry
- DHT Marine Transportation
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- DHT Consumer Discretionary
- ANIP Health Care
- Exchange
- DHT Nasdaq
- ANIP Nasdaq
- Market Cap
- DHT 1.7B
- ANIP 1.4B
- IPO Year
- DHT 2005
- ANIP N/A
- Fundamental
- Price
- DHT $11.02
- ANIP $64.14
- Analyst Decision
- DHT Strong Buy
- ANIP Strong Buy
- Analyst Count
- DHT 4
- ANIP 9
- Target Price
- DHT $13.75
- ANIP $80.56
- AVG Volume (30 Days)
- DHT 1.7M
- ANIP 255.0K
- Earning Date
- DHT 08-11-2025
- ANIP 08-05-2025
- Dividend Yield
- DHT 8.62%
- ANIP N/A
- EPS Growth
- DHT 4.76
- ANIP N/A
- EPS
- DHT 1.10
- ANIP N/A
- Revenue
- DHT $563,104,000.00
- ANIP $674,068,000.00
- Revenue This Year
- DHT N/A
- ANIP $30.84
- Revenue Next Year
- DHT $26.57
- ANIP $7.39
- P/E Ratio
- DHT $10.13
- ANIP N/A
- Revenue Growth
- DHT N/A
- ANIP 30.27
- 52 Week Low
- DHT $8.67
- ANIP $52.50
- 52 Week High
- DHT $12.32
- ANIP $77.00
- Technical
- Relative Strength Index (RSI)
- DHT 45.40
- ANIP 53.23
- Support Level
- DHT $10.79
- ANIP $64.15
- Resistance Level
- DHT $11.25
- ANIP $66.97
- Average True Range (ATR)
- DHT 0.23
- ANIP 1.65
- MACD
- DHT -0.01
- ANIP -0.06
- Stochastic Oscillator
- DHT 41.22
- ANIP 52.11
About DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. The group generates revenues from time charter and spot market operations. It operates through integrated management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from the shipping revenues.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.